Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

May 11, 2027

Study Completion Date

May 11, 2027

Conditions
Osteogenic Sarcoma Recurrent
Interventions
DRUG

Iscador*P

Iscador P given for 2 cycles with follow up imaging done every 2 cycles. If imaging is negative patient remains on study for 13 cycles. If new lesion is found, then patient is off study.

Trial Locations (2)

77030

RECRUITING

M.D. Anderson Children's Cancer Hospital, Houston

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Iscador AG, Arlesheim, Switzerland.

UNKNOWN

collaborator

Tackle Kids Cancer

UNKNOWN

collaborator

Susan Zabransky Hughes Foundation

UNKNOWN

lead

Hackensack Meridian Health

OTHER